Production of an antigenic peptide by insulin-degrading enzyme

被引:52
|
作者
Parmentier, Nicolas [1 ,2 ]
Stroobant, Vincent [1 ,2 ]
Colau, Didier [1 ,2 ]
de Diesbach, Philippe [3 ]
Morel, Sandra [1 ,2 ]
Chapiro, Jacques [1 ,2 ]
van Endert, Peter [4 ,5 ]
Van den Eynde, Benoit J. [1 ,2 ]
机构
[1] Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium
[2] Catholic Univ Louvain, Cellular Genet Unit, Duve Inst, B-1200 Brussels, Belgium
[3] Catholic Univ Louvain, Cell Unit, Duve Inst, B-1200 Brussels, Belgium
[4] INSERM, U103, Paris, France
[5] Univ Paris 05, Fac Med Rene Descartes, Paris, France
关键词
CYTOLYTIC T-LYMPHOCYTES; TRIPEPTIDYL-PEPTIDASE; CELL RESPONSES; ANTIBODY; 57B; GENERATION; IDENTIFICATION; PURIFICATION; DEGRADATION; PROTEASOME; MELANOMA;
D O I
10.1038/ni.1862
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Most antigenic peptides presented by major histocompatibility complex (MHC) class I molecules are produced by the proteasome. Here we show that a proteasome-independent peptide derived from the human tumor protein MAGE-A3 is produced directly by insulin-degrading enzyme (IDE), a cytosolic metallopeptidase. Cytotoxic T lymphocyte recognition of tumor cells was reduced after metallopeptidase inhibition or IDE silencing. Separate inhibition of the metallopeptidase and the proteasome impaired degradation of MAGE-A3 proteins, and simultaneous inhibition of both further stabilized MAGE-A3 proteins. These results suggest that MAGE-A3 proteins are degraded along two parallel pathways that involve either the proteasome or IDE and produce different sets of antigenic peptides presented by MHC class I molecules.
引用
收藏
页码:449 / U114
页数:8
相关论文
共 50 条
  • [21] Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease:: review and hypothesis
    Qiu, WQ
    Folstein, MF
    NEUROBIOLOGY OF AGING, 2006, 27 (02) : 190 - 198
  • [22] Insulin-Degrading Enzyme as a Therapeutic Target in Diabetes
    Abdul-Hay, Samer O.
    Caulfield, Thomas R.
    Leissring, Malcolm A.
    DIABETES, 2012, 61 : A615 - A615
  • [24] Hydroxypyridinethione Inhibitors of Human Insulin-Degrading Enzyme
    Adamek, Rebecca N.
    Suire, Caitlin N.
    Stokes, Ryjul W.
    Brizuela, Monica K.
    Cohen, Seth M.
    Leissring, Malcolm A.
    CHEMMEDCHEM, 2021, 16 (11) : 1775 - 1787
  • [25] Human Insulin-Degrading Enzyme Working Mechanism
    Amata, Orazio
    Marino, Tiziana
    Russo, Nino
    Toscano, Marirosa
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (41) : 14804 - 14811
  • [26] IDENTIFICATION OF ZINC LIGANDS OF THE INSULIN-DEGRADING ENZYME
    PERLMAN, RK
    ROSNER, MR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (52) : 33140 - 33145
  • [27] Insulin-degrading enzyme: is it suitable for diabetes treatment?
    Grune, Tilman
    CELL CYCLE, 2015, 14 (16) : 2553 - 2553
  • [28] Modulation of the Activity of the Insulin-Degrading Enzyme by Aß Peptides
    Kemeh, Merc M.
    Lazo, Noel D.
    ACS CHEMICAL NEUROSCIENCE, 2023, 14 (16): : 2935 - 2943
  • [29] Nitric oxide inhibits insulin-degrading enzyme
    Cordes, Crystal
    Bennett, Robert G.
    Hamel, Frederick G.
    DIABETES, 2006, 55 : A561 - A561
  • [30] STRUCTURE, FUNCTION, AND REGULATION OF INSULIN-DEGRADING ENZYME
    Hulse, Raymond E.
    Ralat, Luis A.
    Tang, Wei-Jen
    VITAMINS AND HORMONES INSULIN AND IGFS, 2009, 80 : 635 - 648